EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Enriched class II HLA inherence in patients with checkpoint inhibitor‐associated bullous pemphigoid

Sophia Gandarillas iD, Adam Berger, Ryan Stephenson, Darius Mehregan, Bahar Dasgeb

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Sophia Gandarillas und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Immune Checkpoint Inhibitors, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma, with increasing annual incidence worldwide, is one of the deadliest cutaneous malignancies often treated with immunotherapy, which has led to commonly encountered immune‐related adverse events (irAEs) including bullous pemphigoid (BP). The relation between an individual's HLA inheritance and risk in development of BP is well studied. The development of BP as an irAE in melanoma patients receiving immunotherapy is also well reported and considered to be related to the expression of BP180 in malignant melanoma. In presented work, the association of enriched presence of certain HLA alleles and haplotypes that increase risk of developing BP as an irAE has been investigated in seven cutaneous cancer patients who presented with immunotherapy‐associated BP, diagnosed by skin biopsy and positive serology for anti‐BP 180 autoantibody. Their HLA typing revealed an enriched presence of certain BP‐related HLA alleles, and haplotypes, particularly HLA‐DQB1*03:01, which was present in all seven patients, whilst its occurrence in the general population is very low. Additionally, some patients had more than one and in a few patients had the whole haplotype of BP related HLA. Not only can such enriched presence be considered a role in risk stratification to initiate or continue immunotherapy, but it may shed a light to existing disease genotypes that can become unmasked to phenotypic clinically presenting BP due to immunotherapy rather than just a random AE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousImmune Checkpoint InhibitorsMelanomaSkin NeoplasmsHLA-DQ beta-ChainsHumansMaleFemaleAgedMiddle AgedHaplotypesAutoantibodiesAged, 80 and overNon-Fibrillar CollagensCollagen Type XVIIAutoantigensAllelesHistocompatibility TestingSkin

Stichwörter der Autor:innen

HLAbullous pemphigoid (BP)checkpoint inhibitorsimmunotherapymelanomarituximab

Substanzen

Immune Checkpoint InhibitorsHLA-DQ beta-ChainsHLA-DQB1 antigenAutoantibodiesNon-Fibrillar CollagensCollagen Type XVIIAutoantigens

Autor:innen und Institutionen

  • School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Department of Dermatology, Wayne State University, Detroit, MI, USA.

ORCID-Profile: Sophia Gandarillas

Zitieren

APA

Gandarillas, S., Berger, A., Stephenson, R., Mehregan, D., & Dasgeb, B. (2025). Enriched class II HLA inherence in patients with checkpoint inhibitor‐associated bullous pemphigoid. International Journal of Dermatology. https://doi.org/10.1111/ijd.17563

Vancouver

Gandarillas S, Berger A, Stephenson R, Mehregan D, Dasgeb B. Enriched class II HLA inherence in patients with checkpoint inhibitor‐associated bullous pemphigoid. International Journal of Dermatology. 2025. doi:10.1111/ijd.17563

BibTeX
@article{Gandarillas2025,
  author = {Gandarillas, Sophia and Berger, Adam and Stephenson, Ryan and Mehregan, Darius and Dasgeb, Bahar},
  title = {Enriched class II HLA inherence in patients with checkpoint inhibitor‐associated bullous pemphigoid},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17563}
}
Kostenlos starten →